---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-012483"
form_type: "8-K"
ticker: "ANIX"
cik: "0000715446"
company_name: "Anixa Biosciences Inc"
filed_at: "2023-04-17T23:59:59+00:00"
generated_at: "2026-06-17T01:38:59.665254+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Anixa Biosciences and Cleveland Clinic report positive Phase 1 data for breast cancer vaccine

## Summary
- Phase 1 trial of triple-negative breast cancer vaccine showed antigen-specific T cell responses at all dose levels.
- Trial funded by U.S. Department of Defense; Anixa is exclusive worldwide licensee from Cleveland Clinic.
- Participants were tumor-free women with history of TNBC, curatively treated, at high risk of recurrence.
- Phase 1a study evaluates safety, MTD, and immune response; not designed to measure recurrence prevention.

## SEC filing metadata
- accession: 0001493152-23-012483
- form_type: 8-K
- ticker: ANIX
- cik: 0000715446
- company_name: Anixa Biosciences Inc
- filed_at: 2023-04-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/715446/000149315223012483/0001493152-23-012483-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/715446/000149315223012483/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-012483
- JSON: https://secwatch.observer/filing/0001493152-23-012483.json
- Plain text: https://secwatch.observer/filing/0001493152-23-012483.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.